Delving into the Latest Updates on Traneurocin with Synapse

Overview

Drug Type

Small molecule drug

Synonyms

NEUROSIVIR

+ [2]

Target-

Mechanism

Neurogenesis stimulants

Therapeutic Areas

Active Indication

Inactive Indication

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	-	Biomed Industries, Inc.	-
Severe Acute Respiratory Syndrome	IND Application	NZ	NeuroActiva, Inc.	01 Nov 2020
Severe Acute Respiratory Syndrome	IND Application	US	NeuroActiva, Inc.	01 Nov 2020
Severe acute respiratory infection	Discovery	US	NeuroActiva, Inc.	15 Jun 2022
COVID-19	Discovery	US	NeuroActiva, Inc.	01 Nov 2020
COVID-19	Discovery	NZ	NeuroActiva, Inc.	01 Nov 2020
Nerve Degeneration	Discovery	US	NeuroActiva, Inc.	15 Sep 2020
Dementia, Vascular	Discovery	NZ	NeuroActiva, Inc.	15 Sep 2018
Lewy Body Disease	Discovery	NZ	NeuroActiva, Inc.	15 Sep 2018
Mild cognitive disorder	Discovery	NZ	NeuroActiva, Inc.	15 Sep 2018

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03538522 (AAIC 12022 \| AAIC 22022) Manual	Phase 2	Alzheimer Disease	56	Traneurocin	(ezksgoulym) = NA-831 was well-tolerated at 30 mg/day for 24 weeks, and no serious adverse events were observed. lydxneneuq (hpjtpouqnj ) View more	Positive	20 Dec 2022
				Placebo
AAIC2018	Not Applicable	Alzheimer Disease	32	Placebo	zubozztqof(xuesjntilq) = kpkwpygfkw fvgtwdkymi (exyplsgxbf )	-	01 Jul 2018
				NA-831 5 mg	zubozztqof(xuesjntilq) = dzqkxtgecs fvgtwdkymi (exyplsgxbf )